Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn’s Disease: a Phase 2a Study

MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn’s disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study.